<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261712</url>
  </required_header>
  <id_info>
    <org_study_id>CRN00808-05</org_study_id>
    <secondary_id>U1111-1245-5276</secondary_id>
    <secondary_id>2019-002193-31</secondary_id>
    <nct_id>NCT04261712</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)</brief_title>
  <official_title>An Open Label, Long-term Extension Study to Evaluate the Safety and Efficacy of CRN00808 in Subjects With Acromegaly (ACROBAT Advance)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crinetics Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crinetics Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy
      of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2
      biased agonist) in subjects with acromegaly.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 29, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) throughout the study</measure>
    <time_frame>Week 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in insulin-like growth factor-1 (IGF-1) level</measure>
    <time_frame>Week 16, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in growth hormone (GH) level</measure>
    <time_frame>Week 16, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGF-1 level (untreated group only)</measure>
    <time_frame>Screening, Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Paltusotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paltusotine</intervention_name>
    <description>Paltusotine, capsules, once daily by mouth</description>
    <arm_group_label>Paltusotine</arm_group_label>
    <other_name>CRN00808</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects 18 to 75 years of age

          2. Completed one of the parent studies (Acrobat Evolve [CRN00808-02] or Acrobat Edge
             [CRN00808-03]) OR subjects with uncontrolled acromegaly who are not currently treated
             with acromegaly medications

          3. Females must be non-pregnant and non-lactating, and either surgically sterile,
             post-menopausal, or using effective method(s) of birth control

          4. Willing to provide signed informed consent

        Exclusion Criteria:

          1. Clinically significant concomitant disease including, but not limited to,
             cardiovascular disease; moderate or severe renal insufficiency; or significant liver
             disease (including cirrhosis)

          2. Pituitary radiation since completing participation in parent studies OR have had
             radiation treatment at any time (untreated subjects)

          3. History or presence of malignancy except adequately treated basal cell and squamous
             cell carcinomas of the skin within the past 5 years

          4. Positive test at Screening for HIV, hepatitis B surface antigen (HBsAg) or hepatitis C
             antibody (HCV-Ab).

          5. History of alcohol or substance abuse in the past 12 months

          6. Use of any investigational drug (other than paltusotine) within the past 30 days or 5
             half-lives, whichever is longer before Screening

          7. Any condition that in the opinion of the investigator would jeopardize the subject's
             appropriate participation in this study.

          8. Cardiovascular conditions or medications associated with prolonged QT or those which
             predispose subjects to heart rhythm abnormalities

          9. Subjects with symptomatic cholelithiasis

         10. Subjects with clinically significant abnormal findings during the Screening Period,
             and any other medical condition(s) or laboratory findings that, in the opinion of the
             Investigator, might jeopardize the subject's safety or ability to complete the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Allegheny Endocrinology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem Klinika Kozpont I. sz. Belgyogyaszati Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Naţional de Endocrinologie &quot;C.I. Parhon&quot;</name>
      <address>
        <city>Bucuresti</city>
        <zip>011863</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <keyword>ACROBAT</keyword>
  <keyword>ADVANCE</keyword>
  <keyword>Paltusotine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

